http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-040854-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d327532bd0a0c479900b934c996fcb27 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55511 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-365 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P33-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P33-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P33-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0003 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P33-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| filingDate | 2003-08-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_74d9349c670dec91b6de9ba6f8677f54 |
| publicationDate | 2005-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-040854-A1 |
| titleOfInvention | A PRODUCT FOR THE FIGHT OF TICKETS AND A PROCESS FOR THE PREPARATION OF THIS PRODUCT |
| abstract | A product for the fight of ticks of the type of biological drug or vaccine drug destined for the veterinary market to combat ticks in bovine herds of tropical and subtropical regions of the world, characterized in that its form of action is based on a novel vehicle that allows solubilize injectable eprinomectin, in doses of 200-250 ug / kg body weight, with specific tick antigens, more specifically because its main action is to vehicle at the same time and by injectable vpia, a last generation macrocyclic lactone and antigens against Ticks The product can, at the same time, solubilize doses from 0.5% to 3.5% of eeprinomectin and present 2 specific antigens that end up producing active and gradual immunity against ticks in the animal. Claim 12: A process for the preparation of the product according to any one of claims 1 to 3, characterized in that it comprises two phases, the first being a phase at a temperature of 50 ° and the second a phase at a temperature of + 4 ° C Claim 14: A process for the preparation of the product according to claim 12, characterized in that the second phase consists of the following stages: the aqueous antigens formed by the suspensions of recombinant protein material from the digestive system of the Boophilus microplus tick and obtained by bacterial fermentation, are added to the Eprinomectin solution. The Eprinomectin solution is prepared by dissolving the drug in a water-soluble vehicle in a concentration that can range from 0.25% to 20% w / v (eprinomectin in a water-soluble vehicle). The concentration of Eprinomectin in the final product may be 0.5% to 3.5% w / v and the dose to be administered of the final product should be 200 to 250 ug of eprinomectin / kg of animal weight. Once a homogeneous suspension is obtained, it is slowly placed under strong agitation on the mixture 1 of active oil and tension at + 4 ° C. |
| priorityDate | 2002-08-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
| Predicate | Subject |
|---|---|
| isDiscussedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID426110345 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6450531 |
Total number of triples: 19.